Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Metabolic diseases like diabetes mellitus cause bone healing deficiencies. We found significant impairment of bone regeneration, osteogenic differentiation and proliferation in diabetic bone. Moreover recent studies suggest a highly underestimated importance of GDF8 (Myostatin) in bone metabolism. Our goal was to analyze the role of GDF8 as a regulator of osteogenic differentiation, proliferation and bone regeneration. We used a murine tibial defect model in diabetic (Lepr db−/−) mice. Myostatin-Inhibitor Follistatin was administered in tibial bony defects of diabetic mice. By means of histology, immunohistochemistry and QRT-PC osteogenesis, differentiation and proliferation were analyzed. Application of Myostatin-inhibitor showed a significant improvement in diabetic bone regeneration compared to the control group (6.5 fold, p < 0.001). Immunohistochemistry revealed a significantly higher proliferation (7.7 fold, p = 0.009), osteogenic differentiation (Runx-2: 3.7 fold, p = 0.011, ALP: 9.3 fold, p < 0.001) and calcification (4.9 fold, p = 0.024) in Follistatin treated diabetic animals. Therapeutical application of Follistatin, known for the importance in muscle diseases, plays an important role in bone metabolism. Diabetic bone revealed an overexpression of the catabolic protein Myostatin. Antagonization of Myostatin in diabetic animals leads to a restoration of the impaired bone regeneration and represents a promising therapeutic option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543
GDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527
Relationships between fat and bone
Reid, I. R. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0492-z · Cited by 475
Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis
Amthor, H., Nicholas, G., McKinnell, I., Kemp, C. F., Sharma, M., Kambadur, R., & Patel, K. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.01.046 · Cited by 401
The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt, K. I., Thomson, R. E., Connor, T., Turner, B. J., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211134 · Cited by 225
Winbanks, C. E., Weeks, K. L., Thomson, R. E., Sepulveda, P. V., Beyer, C., Qian, H., Chen, J. L., Allen, J. M., Lancaster, G. I., Febbraio, M. A., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201109091 · Cited by 218
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
Rodino‐Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K., & Mendell, J. R. (2009) · Muscle & Nerve · doi:10.1002/mus.21244 · Cited by 194
Cited by
Muscle, Bone, and Fat Crosstalk: The Biological Role of Myokines, Osteokines, and Adipokines
Kirk, B., Feehan, J., Lombardi, G., & Duque, G. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00599-y · Cited by 510
Myokines: The endocrine coupling of skeletal muscle and bone
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.07.010 · Cited by 272
Osteosarcopenia: where osteoporosis and sarcopenia collide
Clynes, M. A., Gregson, C. L., Bruyère, O., Cooper, C., & Dennison, E. M. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa755 · Cited by 268
Lee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59
“It is also known that MSTN inhibitors, like follistatin and the ACVR2B/Fc decoy receptor, can have significant effects on bone repair and bone density in vivo (39, 40, 55, 56), but because these inhibitors can also block activin signaling, the identities of the key ligands being blocked in these studies is not clear.”
Bone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
“FST has been found to alleviate myo-statin-induced bone degeneration in Type 2 diabetes mellitus (T2DM) mice [99].”
Background
Metadata
- Authors
- Wallner, C., Jaurich, H., Wagner, J. M., Becerikli, M., Harati, K., Dadras, M., Lehnhardt, M., & Behr, B.
- Venue
- Scientific Reports
- Published
- 2017-08-29
- Volume
- 7
- Issue
- 1
- Pages
- 9878-9878
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2749231113
- Cited by
- 51
- References
- 7
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. https://app.cochat.ai/papers/10.1038/s41598-017-10404-z
- The paper
- Wallner, C., Jaurich, H., Wagner, J. M., Becerikli, M., Harati, K., Dadras, M., Lehnhardt, M., & Behr, B. (2017). Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Scientific Reports. https://doi.org/10.1038/s41598-017-10404-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.